Can a targeted antibody stop severe hepatitis from destroying Children's livers?
NCT ID NCT07744919
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial tests whether a medicine called emapalumab, which calms a specific part of the immune system, can prevent liver failure in children aged 1 year and older with severe hepatitis that hasn't improved with steroids. The study includes a screening group to observe all severe hepatitis cases and an intervention group that receives emapalumab alongside steroids. The goal is to see if this combination can control the immune attack on the liver and avoid the need for a transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- emapalumab (a monoclonal antibody) combined with steroids
- What this could lead to
- If successful, this could offer a new treatment to prevent liver failure in children with severe hepatitis, potentially avoiding the need for liver transplants.
- What could go wrong
- This is an early-phase study with a small number of participants. The drug may not work for all children, and there are risks of side effects from immune suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arthur M. Blank Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for immunotherapy side effects: blood filtering may replace steroids
- New hope for HIV patients with Hard-to-Treat hepatitis c
- Can this IV drug help avoid liver transplants in heavy drinkers?
- New app aims to empower hepatitis delta patients in their own care
- Prison TB study tests shorter prevention course
- 120,000-Person study hopes to crack the code of chronic illness